Angiostatin, the N-terminal four kringles (K1-4) of plasminogen, blocks tum
or-mediated angiogenesis and has great therapeutic potential. However, angi
ostatin's mechanism of anti-angiogenic action is unclear. We found that bov
ine arterial endothelial (BAE) cells adhere to angiostatin in an integrin-d
ependent manner and that integrins alpha (v)beta (3), alpha (9)beta (1), an
d to a lesser extent alpha (4)beta (1) specifically bind to angiostatin. al
pha (v)beta (3) is a predominant receptor for angiostatin on BAE cells, sin
ce a function-blocking antibody to alpha (v)beta (3) effectively blocks adh
esion of BAE cells to angiostatin, but an antibody to alpha (9)beta (1) doe
s not. e-Aminocaproic acid, a Lys analogue, effectively blocks angiostatin
binding to BAE cells, indicating that an unoccupied Lys-binding site of the
kringles may be required for integrin binding. It is known that other plas
minogen fragments containing three or five kringles (K1-3 or K1-5) have an
anti-angiogenic effect, but plasminogen itself does not. We found that K1-3
and K1-5 bind to alpha (v)beta (3), but plasminogen does not. These result
s suggest that the anti-angiogenic action of angiostatin may be mediated vi
a interaction with alpha (v)beta (3). Angiostatin binding to alpha (v)beta
(3) does not strongly induce stress-fiber formation, suggesting that angios
tatin may prevent angiogenesis by perturbing the alpha (v)beta (3)-mediated
signal transduction that may be necessary for angiogenesis.